igella sativa seeds and Febrile Neutropenia

Not Applicable

• Conditions: Cancer; brain tumors

• Registration Number: PACTR201503001039326
• Lead Sponsor: high institute of public health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-18
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Other
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

children (2-18)years with primary brain tumors.

Exclusion Criteria

1. children with any type of cancer other than brain tumors.
2. children with relapsed brain tumors.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prevention of febrile neutropenia during chemotherapy cycles;number of admissions to hospital as a result of febrile neutropenia.;Length of hospital stay upon admission as a result of Febrile Neutropenia.

Secondary Outcome Measures

Name	Time	Method
improvement of chemotherapy-related haematological and GIT toxicities